MON-521 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC)

Background: ATC is aggressive, with a low 5-year patient (pt)-survival rate. Apart from recent advances in treating ATCs in pts with BRAF mutations, systemic treatments have limited efficacy and duration of response is short. In a small, phase 2 study conducted in Japan, 24% of pts with ATC achieved...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirth, Lori J, Brose, Marcia S, Sherman, Eric J, Misir, Soamnauth, Xie, Sharon, Almonte, Ana, Ye, Weifei, Licitra, Lisa, Schlumberger, Martin, Sherman, Steven I, Cabanillas, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208145/
http://dx.doi.org/10.1210/jendso/bvaa046.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208145/
http://dx.doi.org/10.1210/jendso/bvaa046.002

Ejemplares similares